Search
01/12/2021
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
Rubio-Viqueira, B, Tarruella, MM, Lazaro, M, Estevez, SV, Cordoba-Ortega, JF, Maiques, IM, Gonzalez, JG, Cordellat, AB, Valdivia-Bautista, J, Arenas, CG, Torres, JMS. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study. Lung Cancer Management. 2021; 10(4)DOI:10.2217/lmt-2021-0008. PMID:34899993. IF:(Q/D).
01/12/2021
Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group
Caamano, AG, Vicente, AMGM, Maroto, P, Antolin, AR, Sanz, J, Gonzalez, MAV, Climent, MA. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group. Current Oncology. 2021; 28(6)DOI:10.3390/curroncol28060428. PMID:34940067. IF:3.109(Q3/8D).
01/12/2021
Immunotherapy-induced isolated ACTH deficiency in cancer therapy
Iglesias, P, Peiro, I, Biagetti, B, Paja-Fano, M, Cobo, DA, Gomez, CG, Mateu-Salat, M, Genua, I, Majem, M, Riudavets, M, Gavira, J, Lamas, C, Pombo, AF, Guerrero-Perez, F, Villabona, C, Agricola, JMC, Webb, SM, Diez, JJ. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. ENDOCRINE-RELATED CANCER. 2021; 28(12)DOI:10.1530/ERC-21-0228. PMID:34609950. IF:5.905(Q1/3D).
01/12/2021
Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma
Riudavets, M, Bosch-Barrera, J, Cabezon-Gutierrez, L, Tain, PD, Hernandez, A, Alonso, M, Blanco, R, Galvez, E, Insa, A, Mielgo, X, Moran, T, Ponce, S, Roa, D, Sanchez, JM, Majem, M. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical & Translational Oncology. 2021; 23(12)DOI:10.1007/s12094-021-02661-2. PMID:34292495. IF:3.340(Q3/7D).
01/12/2021
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin
Moura, DS, Pena-Chilet, M, Varela, JAC, Alvarez-Alegret, R, Agra-Pujol, C, Izquierdo, F, Ramos, R, Ortega-Medina, L, Martin-Davila, F, Castilla-Ramirez, C, Hernandez-Leon, CN, Romagosa, C, Salgado, MAV, Lavernia, J, Bague, S, Mayodormo-Aranda, E, Vicioso, L, Barcelo, JEH, Rubio-Casadevall, J, de Juan, A, Fiano-Valverde, MC, Hindi, N, Lopez-Alvarez, M, Lacerenza, S, Dopazo, J, Gutierrez, A, Alvarez, R, Valverde, C, Martinez-Trufero, J, Martin-Broto, J. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. Molecular Oncology. 2021; 15(12)DOI:10.1002/1878-0261.12996. PMID:33983674. IF:7.449(Q1/3D).
01/12/2021
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Martin-Broto, J, Lopez-Alvarez, M, Moura, DS, Ramos, R, Collini, P, Romagosa, C, Bague, S, Renne, SL, Barisella, M, Velasco, V, Coindre, JM, Lopez-Lopez, D, Dopazo, J, Gambarotti, M, Braglia, L, Merlo, DF, Palmerini, E, Stacchiotti, S, Quagliuolo, VL, Lopez-Pousa, A, Grignani, G, Blay, JY, Brunello, A, Gutierrez, A, Valverde, C, Hindi, N, Dei Tos, AP, Picci, P, Casali, PG, Gronchi, A. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. MOLECULAR CANCER THERAPEUTICS. 2021; 20(12)DOI:10.1158/1535-7163.MCT-21-0315. PMID:34552008. IF:6.011(Q2/3D).